Apremilast as anti-pruritic treatment in patients with prurigo nodularis

Herlev and Gentofte Hospital0 个研究点目标入组 20 人开始时间: 2017年2月3日最近更新: 2019年4月30日

适应症

试验速览

暂无简介。

•> 18 years of age
•PN verified diagnosis by characteristic clinical features
•Moderate to severe PN
•Failure of local steroid and light treatment to control disease and symptoms.
•Be able to speak and understand Danish.
•Patients must have given their informed consent to the protocol and to the clinical procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients who have received any local anti-inflammatory treatment 2 weeks prior to day 0
•Patients who have received any systemic anti-inflammatory treatment 4 weeks prior to day 0
•Patients who have received any other study medication 4 weeks prior to day 0
•Patients with other clinically significant disorders
•Patients with active TB/serious infections
•Any psychiatric condition which in the Investigators opinion would preclude the patient from adhering to the protocol or completing the study per protocol
•Women of child-bearing potential must use effective contraception which includes IUD, oral, injected or implanted hormonal device, hormone patch, vaginal hormonal ring, sterilization, occlusive cap or condom with spermicidal cream. Post-menopausal women (> 12 months of amenorrhea) are allowed not to use contraception.
•Patients who have received any live vaccines 6 weeks prior to day 0 or who are planning to receive a live vaccine during the study

发起方